Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs NeoGenomics Inc. Common Stock (NEO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs NeoGenomics Inc. Common Stock — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.9 (market cap $8.87B), while NeoGenomics Inc. Common Stock trades at $16.85 (market cap $2.14B). The key difference: Kymera Therapeutics Inc. Common Stock is far larger — about 4.1× NeoGenomics Inc. Common Stock's market cap, and Kymera Therapeutics Inc. Common Stock is more actively traded (779,107 versus 2,228,400). Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and NeoGenomics Inc. Common Stock for 0 Days on average.
| KYMR | NEO | |
|---|---|---|
Market Cap | $8.87B | $2.14B |
Volume | 779,107 | 2,228,400 |
Sector | Health | Health |
52-Week High | $127.31 | $19.91 |
52-Week Low | $55.80 | $7.19 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $8.26B | $2.44B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About NeoGenomics Inc. Common Stock
NeoGenomics, Inc. is a US cancer diagnostics company that provides genomic and pathology testing services, offering an oncology-focused testing menu used by oncologists, pathologists, and hospital systems across the cancer care continuum.
Read more on NEO →
